Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
17
17 articles ont été cités au moins 17fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 730
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
57
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
23
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Sorbonne Université · Hôpital Rothschild · Observatoire Français de la Sclérose en Plaques
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis
2026ArticleNeurology
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis
2025ArticleJAMA neurology
Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the RESPONSE study to the general French population
2025ArticleMultiple Sclerosis Journal
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
2024ArticleJAMA neurology
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society
2024ArticleMultiple Sclerosis Journal
COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022
2024ArticleMultiple Sclerosis Journal
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study
2023ArticleMultiple Sclerosis Journal
The radiologically isolated syndrome: revised diagnostic criteria
2023ArticleBrain - A Journal of Neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL FONDATION A DE ROTHSCHILD
25 R MANIN, 75019 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Archives of neurology · 2009
Brain : a journal of neurology · 2023
Abstract The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1–2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Multiple sclerosis (Houndmills, Basingstoke, England) · 2023 · Multicenter Study
Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, et al.
Brain : a journal of neurology · 2023 · Journal Article
Lebrun-Frénay C, Okuda DT, Siva A, Landes-Chateau C, et al.
JAMA network open · 2021 · Journal Article
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, et al.
JAMA neurology · 2020 · Journal Article
Louapre C, Collongues N, Stankoff B, Giannesini C, et al.
Journal of neurology · 2025 · Journal Article
Deschamps R, Boudot de la Motte M, Chaugne E, Lamirel C, et al.
European journal of neurology · 2025 · Journal Article
Leger B, Gueguen A, Lecler A, Boudot de la Motte M, et al.
JAMA neurology · 2020 · Journal Article
Vukusic S, Rollot F, Casey R, Pique J, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) · 2019 · Journal Article
Durozard P, Maarouf A, Boutiere C, Ruet A, et al.
Multiple sclerosis and related disorders · 2025 · Journal Article
Mandia D, Shor N, Carlson AK, Obusez E, et al.
Archives of neurology · 2009 · Journal Article
Lebrun C, Bensa C, Debouverie M, Wiertlevski S, et al.
Multiple sclerosis and related disorders · 2025 · Journal Article
Mandia D, Shor N, Carlson AK, Obusez E, et al.
Journal of neurology · 2026 · Journal Article
Brochard V, Lecler A, Januel E, Chaugne E, et al.
Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody
Background:A paradoxical discrepancy between severe peripapillary retinal nerve fiber layer (pRNFL) atrophy and good visual outcome had been reported in patients with myelin oligodendrocyte glycoprotein-immunoglobulin G
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Background:Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.Objectives:We aimed to extend these data
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Background:Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.Objectives:We aimed to extend these data
Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody
Background:A paradoxical discrepancy between severe peripapillary retinal nerve fiber layer (pRNFL) atrophy and good visual outcome had been reported in patients with myelin oligodendrocyte glycoprotein-immunoglobulin G
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society
Background:Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by fr
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).